C225

A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division. Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors. This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)